News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

Kyowa Hakko Kirin News Releases

RSS feeds

Search News Releases

Search by Category

Select a Year From Archive

April 17, 2014
Termination of Mogamulizumab Licensing Agreement with Amgen
April 16, 2014
Kyowa Hakko Kirin initiated a Pivotal Phase 3 Trial of Benralizumab (KHK4563) for Severe Asthma in Japan
April 8, 2014
Completion of Construction for the biopharmaceutical API manufacturing facility in the Takasaki Plant
March 31, 2014
Application Seeking Approval for Additional Indication of NESP® for Anemia with Myelodysplastic Syndrome in Japan
March 28, 2014
Matters concerning controlling shareholdersPDF file:New window opens(23KB)
March 25, 2014
Kyowa Hakko Kirin Submits Application for Approval of REGPARA® Tablets 12.5mg in Japan
March 20, 2014
Notice regarding allotment of stock acquisition rights(stock compensation-type stock options)PDF file:New window opens(23KB)
March 19, 2014
New window opensLonza and BioWa Sign POTELLIGENT® CHOK1SV Cell Line Technology Licensing Agreement with arGEN-XPDF file:New window opens(155KB)
March 17, 2014
Approval for Additional Indication for PTCL and CTCL of Mogamulizumab
March 10, 2014
Correction of one section of the Consolidated Financial Summary Fiscal 2013PDF file:New window opens(37KB)
February 28, 2014
Construction to Begin on New IK8 Research Building at Fuji Research Park
February 26, 2014
Correction of one section of the Consolidated Financial Summary Fiscal 2013PDF file:New window opens(46KB)
February 21, 2014
Approval for Additional Indication of REGPARA® Tablets 25mg and 75mg
February 19, 2014
Position and policies concerning the reduction of the minimum investment unitPDF file:New window opens(10KB)
February 19, 2014
Notice regarding stock acquisition rights for the purpose of granting stock compensation-type stock optionsPDF file:New window opens(18KB)
February 10, 2014
Change to Supplemental Application Seeking Approval of Additional Indication for Mogamulizumab
February 4, 2014
Kyowa Hakko Kirin Announces Commencement of Phase 3 Clinical Study of ARQ 197 (Tivantinib) in Patients with Hepatocellular Carcinoma in Japan
February 4, 2014
Correction of figure included in the Kyowa Hakko Kirin Presentation Materials for Fiscal year ended December 2013PDF file:New window opens(85KB)
January 31, 2014
Kyowa Hakko Kirin Fiscal 2013 Results: Strong domestic pharmaceutical sales, forex, and extraordinary gains offset challenging operating environmentPDF file:New window opens(201KB)
January 31, 2014
Consolidated Financial Summary Fiscal 2013PDF file:New window opens(206KB)
January 31, 2014
Appendix to the Fiscal 2013 Consolidated Financial StatementsPDF file:New window opens(234KB)
January 31, 2014
Fiscal 2013 Results PresentationPDF file:New window opens(3,344KB)
January 31, 2014
Kyowa Hakko Kirin to Consolidate and Reorganize Research and Development DivisionsPDF file:New window opens(82KB)
January 23, 2014
Launch of Long-Acting Erythropoiesis-Stimulating Agent NESP® Injection 5 μg Plastic Syringe in Japan
January 20, 2014
Notice of revisions to the Appendix to the Fiscal 2013 Third Quarter Consolidated Financial StatementsPDF file:New window opens(704KB)
January 17, 2014
Approval of Fine Granules of Topina®, an Antiepileptic Agent
January 15, 2014
Addition of Japanese Sites for Pivotal Phase 3 Trial of Mogamulizumab (KW-0761) in Patients with Cutaneous T-Cell Lymphoma
December 23, 2013
Launch of Redesigned BioWa Website
December 20, 2013
Approval for Additional Indication for Unresectable Pancreatic Cancer of 5-FU Injection 250mg and 1000mg
December 20, 2013
Co-Promotion Partnership Agreement for Topical Calcipotriol/Betamethasone Dipropionate in Japan
December 16, 2013
Launch of Kyowa Hakko Kirin Thailand Website
December 11, 2013
New window opensLonza and BioWa Sign POTELLIGENT® CHOK1SV Cell Line Technology Licensing Agreement with MedImmunePDF file:New window opens
December 11, 2013
Launch of Abstral® sublingual tablets for Cancer Pain Treatment in Japan
December 2, 2013
Yokkaichi Plant Closed as Part of Production Facility Reorganization
December 2, 2013
Launch of Kyowa Hakko Kirin Singapore Website
November 28, 2013
Launch of Redesigned Kyowa Hakko Kirin Korea Website
November 22, 2013
Approval for Pediatric Use of Topina®Tablets, an Antiepileptic Agent
November 21, 2013
Kyowa Hakko Kirin Initiates a Global Phase 3 Trial of Istradefylline (KW-6002) for Parkinson's Disease
November 20, 2013
Launch of Sancuso in Taiwan
November 11, 2013
New window opensProStrakan Announces Board ChangesPDF file:New window opens(127KB)
November 11, 2013
Kyowa Hakko Kirin Announces the Development Status of Bardoxolone Methyl (RTA 402) in Patients with Chronic Kidney Disease and Type 2 Diabetes in Japan
October 31, 2013
Results of a Phase 2 Study of KHK4827 in Subjects with Psoriasis in Japan
October 31, 2013
Launch of Nplate in Taiwan
October 29, 2013
Notice of revisions to the Appendix to the Fiscal 2013 Third Quarter Consolidated Financial Statements issued on October 25, 2013PDF file:New window opens(323KB)
October 25, 2013
Kyowa Hakko Kirin Third Quarter Operating Income up 10.9%PDF file:New window opens(122KB)
October 25, 2013
Consolidated Financial Summary Fiscal 2013, Third QuarterPDF file:New window opens(302KB)
October 25, 2013
Appendix to the Fiscal 2013 Third Quarter Consolidated Financial StatementsPDF file:New window opens(301KB)
October 21, 2013
Kyowa Hakko Kirin launched a website content "Invisible Things" for its corporate branding.
View the artistically created films which express the condensed feelings of our company members, called "Commitment to Life"
October 7, 2013
Announcement of Results from a Single Dose Phase 1 Study of a Human Monoclonal Anti-FGF23 Antibody (KRN23) in X-linked Hypophosphatemia in Adults
October 1, 2013
Launch of Redesigned Kyowa Hakko Kirin China Website
September 30, 2013
New window opensProStrakan Announces EU Launch of SancusoPDF file:New window opens(77KB)
September 26, 2013
Subanalyses of the SAVOR clinical trial for Onglyza® will be presented at the 49th Annual Meeting of the European Association for the Study of DiabetesPDF file:New window opens(95KB)
September 20, 2013
Announcement regarding the Marketing Approval of Abstral® sublingual tablets for Cancer Pain Treatment
September 20, 2013
Approval of Long-Acting Erythropoiesis-Stimulating Agent NESP® Injection 5μg Plastic Syringe in Japan
September 13, 2013
Approval of Additional Indication of Long-Acting Erythropoiesis-Stimulating Agent NESP® for Pediatric Patients with renal anemia in Japan
September 13, 2013
Launch of Kyowa Hakko Kirin Hong Kong Corporate Website
September 9, 2013
Kyowa Hakko Kirin Establishes "Singapore Translational Research Laboratory (STRL)"
- Initiates Research Collaboration with the Cancer Science Institute of Singapore and the National University Cancer Institute, Singapore
PDF file:New window opens(77KB)
September 4, 2013
Collaboration with Ultragenyx to Develop and Commercialize KRN23 for X-linked Hypophosphatemia
September 2, 2013
Results of the SAVOR-TIMI53 clinical trial for Onglyza® will be presented at the European Society of Cardiology Congress and published in the New England Journal of MedicinePDF file:New window opens(59KB)
August 27, 2013
Launch of Redesigned Kyowa Hakko Kirin California Website
July 31, 2013
Hisamitsu Pharmaceutical Submits Application Seeking Approval for Additional Indication of Chronic Pain for Fentos® Tape, a Transdermal Long-Acting Cancer Pain Relief Patch
July 31, 2013
Notice of revisions to the figures in Result Presentation for first half of the fiscal year ending December 2013PDF file:New window opens(1399KB)
July 30, 2013
New window opensLonza and BioWa Sign License Agreements with Pfizer, Inc. Allowing Use of Their POTELLIGENT® CHOK1SV Cell Line for Therapeutic Antibody Research and DevelopmentPDF file:New window opens(53KB)
July 30, 2013
New window opensLa Jolla Institute Continues Longtime Collaboration With Kyowa Hakko Kirin California
Signing Extends One of World’s Most Enduring Alliances for Drug Discovery
PDF file:New window opens(275KB)
July 26, 2013
Kyowa Hakko Kirin First Half Operating Income up 6.2%PDF file:New window opens(117KB)
July 26, 2013
Consolidated Financial Summary Fiscal 2013 InterimPDF file:New window opens(255KB)
July 26, 2013
Appendix to the Fiscal 2013 Interim Consolidated Financial StatementsPDF file:New window opens(357KB)
July 26, 2013
FY ending December 2013 First half results presentationPDF file:New window opens(1197KB)
July 19, 2013
Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab
July 16, 2013
Daiichi Fine Chemical Completes Construction of a New Facility for the Manufacture of Bulk PharmaceuticalsPDF file:New window opens(98KB)
July 9, 2013
New window opensProStrakan Announces 3 Abstracts for Sancuso®(Granisetron Transdermal System) Presented at the Multinational Association for Supportive Care in Cancer (MASCC) 2013 Annual MeetingPDF file:New window opens(155KB)
July 8, 2013
Launch of Onglyza® Tablets 2.5mg, 5mg for Type 2 Diabetes
June 28, 2013
Launch of Kyowa Hakko Kirin Taiwan Corporate Website
June 27, 2013
Kyowa Hakko Kirin Submits Application for Approval in Japan for Sustained-Duration G-CSF Product (KRN125)
June 27, 2013
Application Seeking Approval for Additional Indication for REGPARA® Tablets 25mg and 75mg
June 17, 2013
Launch of Renewed Kyowa Hakko Kirin Corporate Website
May 31, 2013
Application Seeking Approval for Additional Indication for Pancreatic Cancer of 5-FU Injection 250mg and 1000mg
May 29, 2013
Launch of NOURIAST® tablets 20 mg, in Japan, a novel antiparkinsonian agent
May 27, 2013
Kyowa Hakko Kirin Subsidiary Chiyoda Kaihatsu
To Transfer Some Operations to Uyeno Kosan
May 24, 2013
Completion of Drug Price Listing and Marketing Authorization Transfer of Onglyza® Tablets 2.5mg, 5mg for Type 2 Diabetes
April 26, 2013
Notice of revisions to the Appendix to the Fiscal 2013 First Quarter Consolidated Financial Statements issued on April 24, 2013PDF file:New window opens(416KB)
April 24, 2013
Kyowa Hakko Kirin Announces Q1 resultsPDF file:New window opens(111KB)
April 24, 2013
Consolidated Financial Summary First Quarter of the Fiscal Year to December 31, 2013PDF file:New window opens(113KB)
April 24, 2013
Appendix to the Fiscal 2013 First Quarter Consolidated Financial StatementsPDF file:New window opens(229KB)
April 4, 2013
An article, "Japan's biggest biotech" is on BioCenturyPDF file:New window opens(57KB)
March 29, 2013
Matters concerning controlling shareholdersPDF file:New window opens(53KB)
March 25, 2013
Approval for manufacturing and marketing of NOURIAST® tablets 20 mg, a novel antiparkinsonian agent
March 25, 2013
Otsuka Obtains Marketing Approval in Japan
for Onglyza® Tablets to Treat Type 2 Diabetes; Transferred Rights to Kyowa Hakko Kirin
March 25, 2013
Approval for Additional Indication of Pheochromocytoma for Dacarbazine Injection 100PDF file:New window opens(14KB)
March 25, 2013
Launch of "MINIRINMELT® OD Tablet 60μg"
A Treatment of Central Diabetes Insipidus
March 22, 2013
Notice regarding allotment of stock acquisition rights(stock compensation-type stock options)PDF file:New window opens(39KB)
March 18, 2013
BioWa Announces Office Relocation to La Jolla, CaliforniaPDF file:New window opens(56KB)
March 8, 2013
Announcement of Results from a Japanese Phase 3 Clinical Trial on the Additional Indication of Chronic Pain for Fentos® Tape (Development Code: HFT-290), a Transdermal Long-Acting Cancer Pain Relief Patch
March 7, 2013
Construction Work Commenced for Drug Product Manufacturing Facility at Takasaki Plant
February 28, 2013
Approval for time-window extension of the thrombolytic agents GRTPA® and ACTIVACIN® up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular diseasePDF file:New window opens(164KB)
February 21, 2013
Pasetocin® and Sawacillin®: Approval for Additional Indication for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitors and either Clarithromycin or Metronidazole
February 21, 2013
Approval for Additional Indications for Intramuscular Administration and Dosage of Leunase® Injection
February 21, 2013
Position and policies concerning the reduction of the minimum investment unitPDF file:New window opens(40KB)
February 21, 2013
Notice regarding stock acquisition rights for the purpose of granting stock compensation-type stock optionsPDF file:New window opens(80KB)
January 31, 2013
Kyowa Hakko Kirin Group: Medium-term Business Plan 2013-2015PDF file:New window opens(56KB)
January 31, 2013
Medium-term business plan FY 2013 to 2015PDF file:New window opens(3891KB)
January 31, 2013
Kyowa Hakko Kirin Fiscal 2012 Results : Record operating income for third consecutive yearPDF file:New window opens(95KB)
January 31, 2013
Consolidated Financial Summary Fiscal 2012 (January 1, 2012-December 31, 2012)PDF file:New window opens(476KB)
January 31, 2013
Appendix to the Fiscal 2012 Consolidated Financial StatementsPDF file:New window opens(268KB)
January 31, 2013
Kyowa Hakko Kirin Fiscal 2012 Results MeetingPDF file:New window opens(432KB)
January 25, 2013
Results of Phase 3 Clinical Trials of KRN125 in Patients with Malignant Lymphoma and Breast Cancer in Japan
January 4, 2013
Completion of a transfer of business involving consolidated subsidiary Hematech, Inc.PDF file:New window opens(8KB)
December 25, 2012
Completion of Construction of a New Facility for Formulation of Solid Dosage Forms at the Ube Plant
December 19, 2012
Announcement Regarding Applications for Approval of Pediatric Indication and Additional Formulation of Topina®, an Antiepileptic Agent
December 13, 2012
Kyowa Hakko Kirin Initiates Pivotal Phase 3 Trial of Mogamulizumab (KW-0761) in Patients with Cutaneous T-Cell Lymphoma in the United States
December 11, 2012
Results of a Phase 2 Clinical Trial on Mogamulizumab (KW-0761) to Treat Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL) in Japan
December 3, 2012
Long-Acting Erythropoiesis Stimulating Agent NESP® INJECTION PLASTIC SYRINGE with Unified Injection Volume Released for Sale
November 21, 2012
Kyowa Hakko Kirin Submits Application for Additional Indication of Pheochromocytoma for Dacarbazine Injection 100
November 13, 2012
Announcement regarding the Filing in Japan of an Application for Marketing Approval of KW-2246 for Cancer Pain Treatment
October 30, 2012
Kyowa Hakko Kirin Announces Discontinuation for Phase 3 Clinical Study of ARQ 197 (Tivantinib) in Combination with Erlotinib in Non-Small-Cell Lung Cancer PatientsPDF file:New window opens(20KB)
October 26, 2012
Kyowa Hakko Kirin Announces Q3 resultsPDF file:New window opens(184KB)
October 26, 2012
Consolidated Financial Summary Fiscal 2012, Third QuarterPDF file:New window opens(232KB)
October 26, 2012
Appendix to the Fiscal 2012 Third Quarter Consolidated Financial StatementsPDF file:New window opens(96KB)
October 26, 2012
Kyowa Hakko Bio Announces Establishment of a Subsidiary and a New Amino Acid Manufacturing Plant in Thailand
October 24, 2012
Fujifilm Kyowa Kirin Biologics to initiate development of biosimilar of bevacizumab, an anti-VEGF humanized monoclonal antibody which has impressive therapeutic effects for cancers such as colorectal cancer
October 19, 2012
Construction work commenced for the biopharmaceutical API manufacturing facility in the Takasaki Plant
October 19, 2012
Kyowa Hakko Kirin Announces Suspension of Early Phase 2 Clinical Study of Bardoxolone methyl (RTA 402) in Patients with Chronic Kidney Disease and Type 2 Diabetes in JapanPDF file:New window opens(14KB)
October 4, 2012
Application Seeking Approval for Additional Indications for Intramuscular Administration and Dosage of Leunase® Injection 5000 KU and Leunase® Injection 10000 KU
October 1, 2012
New window opensProStrakan Acquires Breast Cancer Product for the USPDF file:New window opens(90KB)
October 1, 2012
Launch of Kyowa Hakko Kirin Global Website
September 28, 2012
Application for time-window extension of the thrombolytic agents GRTPA® and ACTIVACIN® up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular diseasePDF file:New window opens(20KB)
September 26, 2012
Conversion of Kyowa Hakko Kirin Korea Co., Ltd. into wholly owned subsidiary
September 14, 2012
Kyowa Hakko Kirin returns to Otsuka Pharmaceutical the rights to develop and market Busulfex®, for use as a part of conditioning regimen prior to hematopoietic progenitor cell transplantation, in Japan and in Asian Countries & Regions
August 31, 2012
Pasetocin® and Sawacillin®: Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitors and either Clarithromycin or Metronidazole
August 30, 2012
Kyowa Hakko Kirin Announces Temporary Suspension of Patient Enrollment for Phase 3 Clinical Study of ARQ 197 (Tivantinib) in Combination with Erlotinib in Non-Small-Cell Lung Cancer PatientsPDF file:New window opens(12KB)
August 23, 2012
Kyowa Hakko Kirin Initiates Pivotal Phase 2 Trial of Mogamulizumab (KW-0761) in Patients with Adult T-cell Leukemia-Lymphoma in the United States and Europe
July 27, 2012
Kyowa Hakko Kirin Announces First Half Results for Fiscal 2012PDF file:New window opens(40KB)
July 27, 2012
Consolidated Financial Summary Fiscal 2012 InterimPDF file:New window opens(208KB)
July 27, 2012
Appendix to the Fiscal 2012 Interim Consolidated Financial StatementsPDF file:New window opens(264KB)
July 27, 2012
FY December 2012 Interim Results MeetingPDF file:New window opens(1206KB)
July 26, 2012
Launch of Apokyn® Subcutaneous Injection 30 mg for Treatment of Parkinson's Disease
July 19, 2012
Kyowa Hakko Kirin Revises ForecastsPDF file:New window opens(56KB)
June 29, 2012
Otsuka Pharmaceutical and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology
May 29, 2012
Launch of POTELIGEO® (Mogamulizumab) Injection in Japan,
a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL)
May 29, 2012
Launch and Co-Promotion of "MINIRINMELT® OD Tablet 120μg / 240μg", A Treatment of Nocturnal Enuresis / Bedwetting
May 25, 2012
Change in the Company Name of JEIL-KIRIN PHARMACEUTICAL INC.
May 7, 2012
Kyowa Medex Launched POTELIGEO® TEST IHC and POTELIGEO® TEST FCM,Companion Diagnostics of POTELIGEO® Injection in Japan
April 26, 2012
Kyowa Hakko Kirin Announces Q1 resultsPDF file:New window opens(48KB)
April 26, 2012
Consolidated Financial Summary First Quarter of the Fiscal Year to December 2012PDF file:New window opens(180KB)
April 26, 2012
Appendix to the Fiscal 2012 First Quarter Consolidated Financial StatementsPDF file:New window opens(216KB)
April 26, 2012
Change of the Name of Kirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd.
April 26, 2012
Notice regarding allotment of stock acquisition rights(stock compensation-type stock options)PDF file:New window opens(80KB)
April 2, 2012
Announcement regarding the Filing in Japan of
an Application for Marketing Approval of KW-6002 for
Parkinson's Disease Treatment
March 30, 2012
New Drug Application Approval for
POTELIGEO® (Mogamulizumab) Injection in Japan,
a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL)
March 30, 2012
Kyowa Medex Receives Approval for
POTELIGEO® TEST IHC and POTELIGEO® TEST FCM,
Companion Diagnostics of POTELIGEO® Injection in Japan
March 30, 2012
Announcement regarding Marketing Authorization Approval in Japan of Apokyn® Subcutaneous Injection 30 mg (Apomorphine Hydrochloride Hydrate) for Treatment of Parkinson's Disease
March 30, 2012
Matters concerning controlling shareholdersPDF file:New window opens(56KB)
March 27, 2012
Establishment of Fujifilm Kyowa Kirin Biologics
-Joint-Venture of Fujifilm and Kyowa Hakko Kirin for the development, manufacturing and sales of biosimilars-
February 24, 2012
Notice regarding completion and status of repurchase of own sharesPDF file:New window opens(48KB)
February 22, 2012
Position and policies concerning the reduction of the minimum investment unitPDF file:New window opens(40KB)
February 22, 2012
Notice regarding stock acquisition rights for the purpose of granting stock compensation-type stock optionsPDF file:New window opens(100KB)
February 1, 2012
Notice regarding status of repurchase of own sharesPDF file:New window opens(48KB)
January 31, 2012
Kyowa Hakko Kirin Fiscal 2011 Results: Record operating income and ordinary incomePDF file:New window opens(84KB)
January 31, 2012
Consolidated Financial Summary Fiscal 2011PDF file:New window opens(568KB)
January 31, 2012
Appendix to the Fiscal 2011 Consolidated Financial StatementsPDF file:New window opens(136KB)
January 31, 2012
Kyowa Hakko Kirin Fiscal 2011 Results (Fiscal year to December 31, 2011)PDF file:New window opens(760KB)
January 31, 2012
Kyowa Hakko Kirin Announces Change of Representative DirectorsPDF file:New window opens(36KB)
January 31, 2012
Withdrawal of domestic application for the additional "chemotherapy-induced anemia" indication for NESPPDF file:New window opens(16KB)
January 6, 2012
Notice regarding status of repurchase of own sharesPDF file:New window opens(48KB)
December 7, 2011
English version of the "Kyowa Hakko Kirin Group CSR Report 2011" has been issued
December 5, 2011
Launch of gastrointestinal prokinetic agents:
NAUZELIN® OD Tablets 5 and NAUZELIN® OD Tablets 10
December 1, 2011
Notice regarding status of repurchase of own sharesPDF file:New window opens(76KB)
November 16, 2011
Fujifilm and Kyowa Hakko Kirin to set up a joint venture for the development of biosimilars
November 15, 2011
Launch of Allelock 0.5% Granules for the Treatment of Allergic Symptoms - New Dosage Form
November 1, 2011
Notice regarding status of repurchase of own sharesPDF file:New window opens(52KB)
October 27, 2011
Kyowa Hakko Kirin Q3 (9 months) Operating Profit up 15.8%PDF file:New window opens(40KB)
October 27, 2011
Consolidated Financial Summary Third Quarter of Fiscal 2011PDF file:New window opens(148KB)
October 27, 2011
Appendix to the Fiscal 2011 Third Quarter Consolidated Financial StatementsPDF file:New window opens(140KB)
October 3, 2011
Notice regarding status of repurchase of own sharesPDF file:New window opens(48KB)
September 2, 2011
Notice regarding status of repurchase of own sharesPDF file:New window opens(52KB)
August 25, 2011
Kyowa Hakko Kirin announces decision to repurchase own sharesPDF file:New window opens(36KB)
August 10, 2011
Kyowa Hakko Kirin Additional Indication Application for Synthesized Penicillin "PASETOCIN®"
August 9, 2011
Kyowa Hakko Kirin Announces Commencement of
Phase 3 International Clinical Study of ARQ 197 (Tivantinib) in Patients with
Non-Small Cell Lung Cancer in Asia
August 2, 2011
Kyowa Hakko Kirin
Fiscal 2011 Interim Results Presentation (January 1- June 30, 2011)
PDF file:New window opens(640KB)
August 2, 2011
Consolidated Financial Summary Fiscal 2011 InterimPDF file:New window opens(128KB)
August 2, 2011
Appendix to the Fiscal 2011 Interim Consolidated Financial StatementsPDF file:New window opens(124KB)
August 2, 2011
Kyowa Hakko Kirin Announces Strong Growth in First Half ProfitsPDF file:New window opens(40KB)
July 26, 2011
Kyowa Hakko Kirin Submitted New Drug Application in Japan for KW-6500
(Apomorphine Hydrochloride Hydrate)
July 20, 2011
Kyowa Hakko Kirin Revises ForecastsPDF file:New window opens(148KB)
June 29, 2011
Kyowa Hakko Kirin announces a Commencement of Phase 3 Clinical Study for KW-3357 in Japan
June 29, 2011
Kyowa Hakko Kirin Announces a Plan to Build a New Pharmaceutical Plant
June 16, 2011
Approval of Additional Indication, Dosage and Administration of Depakene for suppressing the Onset of Migraine Attacks
June 3, 2011
Termination of the North American licensing agreement for KW-6002 (Istradefylline)
June 1, 2011
Ferring and Kyowa Hakko Kirin announce
co-promotion of Desmopressin acetate hydrate orally disintegrating tablet
May 12, 2011
Kyowa Hakko Bio announces the commencement of
commercial production of cis-4-Hydroxy-L-proline
May 10, 2011
Kyowa Hakko Kirin Announces Results of Phase lll Clinical Study of
KW-6002 (Istradefylline) for Parkinson's Disease in Japan
May 10, 2011
New in vitro diagnostic reagents and analyzer for various allergens
Launch announcement for Allerport® HRT and its dedicated analyzer, the Allerport HRT System
May 2, 2011
Notice of revisions to the Appendix to the Fiscal 2011 First Quarter Consolidated Financial StatementsPDF file:New window opens(148KB)
April 27, 2011
Consolidated Financial Summary: First Quarter of the Fiscal Year to December 2011PDF file:New window opens(120KB)
April 27, 2011
(Revised Edition) Appendix to the Fiscal 2011 First Quarter Consolidated Financial StatementsPDF file:New window opens(136KB)
April 27, 2011
Kyowa Hakko Kirin Announces Q1 Growth in Sales, Profits and Net IncomePDF file:New window opens(48KB)
April 26, 2011
Kyowa Hakko Kirin submitted New Drug Application in Japan for KW-0761,
a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL)
April 26, 2011
Kyowa Medex Submitted New Drug Application for
In Vitro Diagnostic Reagent to Detect CCR4 Proteins in Japan
April 20, 2011
Kyowa Medex forms a joint business with Toyobo,
for fully automated gene analysis system GENECUBE®
April 13, 2011
Launch of ROMIPLATE® [250 mcg] for subcutaneous injection
- Platelet producer stimulating thrombopoietin receptors for treatment of chronic
Idiopathic Thrombocytopenic Purpura
March 23, 2011
Regarding the effects of the Tohoku Pacific Coast Earthquake (2nd release)PDF file:New window opens(16KB)
March 14, 2011
Regarding the effects of the Tohoku Pacific Coast EarthquakePDF file:New window opens(16KB)
February 9, 2011
Notice of revisions to the financial summary press release Kyowa Hakko Kirin Fiscal 2010 Sales up 1.7%, Operating income up 46.8%PDF file:New window opens(68KB)
February 1, 2011
Notice of revisions to the Appendix to the Fiscal 2010 Consolidated Financial StatementsPDF file:New window opens(160KB)
January 28, 2011
Kyowa Hakko Kirin Fiscal 2010 Results (Fiscal year to December 31,2010)PDF file:New window opens(1372KB)
January 28, 2011
Consolidated Financial Summary Fiscal 2010PDF file:New window opens(296KB)
January 28, 2011
(Revised Edition) Appendix to the Fiscal 2010 Consolidated Financial StatementsPDF file:New window opens(156KB)
January 28, 2011
(Revised Edition) Kyowa Hakko Kirin Fiscal 2010 Sales up 1.7%, Operating income up 46.8%PDF file:New window opens(64KB)
December 8, 2010
Kyowa Hakko Kirin Announces Results from US Phase 1/2 Clinical Trial of
KW-0761 (Anti-CCR4 Humanized Monoclonal Antibody) in Patients with
Cutaneous T-cell lymphoma
December 7, 2010
Kyowa Hakko Kirin Announces Results from Japan Phase 2 Clinical Trial of
KW-0761 (Anti-CCR4 Humanized Monoclonal Antibody) in Patients with
Recurrent or Relapsed Adult T-Cell Leukemia-Lymphoma (ATL)
October 28, 2010
Kyowa Hakko Kirin Nine-month Sales and Profits Up: Full-year Sales and Operating Income Forecasts RaisedPDF file:New window opens(44KB)
October 28, 2010
Appendix to the Fiscal 2010 Third Quarter Consolidated Financial StatementsPDF file:New window opens(108KB)
October 28, 2010
Consolidated Financial Summary Third quarter of Fiscal 2010 (January 1, 2010 - September 30, 2010)PDF file:New window opens(140KB)
October 27, 2010
Basic Agreement Reached on Sale of Consolidated SubsidiaryPDF file:New window opens(68KB)
October 5, 2010
Kyowa Hakko Kirin to enter licensing agreement with
Lundbeck for A2a antagonist KW-6356
July 28, 2010
Kyowa Hakko Kirin First Half Sales and Profits Up:
Full-year Sales and Operating Profit Forecast Raised
PDF file:New window opens(50KB)
July 28, 2010
Kyowa Hakko Kirin Fiscal 2010 Interim ResultsPDF file:New window opens(1186KB)
July 28, 2010
Appendix to the Fiscal 2010 Interim Consolidated Financial StatementsPDF file:New window opens(113KB)
July 28, 2010
Consolidated Financial Summary Fiscal 2010 Interim (January 1, 2010 - June 30, 2010)PDF file:New window opens(116KB)
June 3, 2010
Kyowa Hakko Kirin to enter out-licensing agreement with Biovail for
anti-Parkinson's disease drug KW-6002 (Istradefylline) in North America
May 25, 2010
Kyowa Hakko Bio announced the reorganization of Yamaguchi Production Center
April 30, 2010
Appendix to the Fiscal 2010 First Quarter Consolidated Financial StatementsPDF file:New window opens(88KB)
April 28, 2010
Consolidated Financial Summary:
First Quarter of the Fiscal Year to December 2010
PDF file:New window opens(136KB)
April 28, 2010
Kyowa Hakko Kirin Announces Q1 Growth in Sales and ProfitsPDF file:New window opens(40KB)
January 29, 2010
Kyowa Hakko Kirin Group:
Medium-term Business Plan 2010-2012
PDF file:New window opens(62KB)
January 29, 2010
Kyowa Hakko Kirin Forecasts 16.4% increase in 2010 Operating Income; 2009 Results in line with Revised ForecastsPDF file:New window opens(71KB)
January 22, 2010
Kyowa Hakko Kirin Revises Down Profit Forecasts
January 8, 2010
Kyowa Hakko Kirin and Reata Pharmaceuticals entered into a licensing agreement on bardoxolone methyl in Japan and other selected Asian markets.
October 29, 2009
Kyowa Hakko Kirin Reports Interim Results in line with Revised ForecastsPDF file:New window opens(68KB)
October 22, 2009
Kyowa Hakko Kirin: Upward Revision of Sales and Profit ForecastsPDF file:New window opens(44KB)
July 29, 2009
Kyowa Hakko Kirin Announces Q1 Results and Revises Forecasts UpwardPDF file:New window opens(113KB)
April 28, 2009
Kyowa Hakko Kirin Fiscal 2008 Sales up 17.4%, Operating Income up 15.2%PDF file:New window opens(48KB)
January 30, 2009
Kyowa Hakko Kirin Third Quarter Results; Revision of full year forecasts; Planned change of fiscal year endPDF file:New window opens(42KB)
January 15, 2009
Kyowa Hakko Kirin announced development policy for the anti-Parkinson's disease drug KW-6002 (Istradefylline)
October 30, 2008
Kyowa Hakko Kirin Interim Results - Integration on schedule -PDF file:New window opens(62KB)

Get Adobe® Reader®You need Adobe® Reader® to view these documents.
Download Adobe® Reader® of Adobe Systems here.



To Page Top